At present, several clinical studies have proven that therapies targeting against IL-1β are successful strategies for relieving pain, inflammation, and recurrent attacks of gout, indicating that targeting IL-1β and its related pathways is effective for gout treatment [69]. Here, IL1B is linked to gout.